Gemini Therapeutics (GMTX) Competitors $59.82 -0.47 (-0.78%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. QGEN, BBIO, MRNA, ELAN, VRNA, ROIV, RVMD, GRFS, ABVX, and RYTMShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Elanco Animal Health (ELAN), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Abivax (ABVX), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Its Competitors QIAGEN BridgeBio Pharma Moderna Elanco Animal Health Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines Grifols Abivax Rhythm Pharmaceuticals Gemini Therapeutics (NASDAQ:GMTX) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Do insiders and institutionals have more ownership in GMTX or QGEN? 75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, GMTX or QGEN? Qiagen has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-59.82Qiagen$2.04B4.95$83.59M$1.6926.86 Is GMTX or QGEN more profitable? Qiagen has a net margin of 18.30% compared to Gemini Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.77% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Qiagen 18.30%14.77%8.87% Does the media prefer GMTX or QGEN? In the previous week, Qiagen had 11 more articles in the media than Gemini Therapeutics. MarketBeat recorded 11 mentions for Qiagen and 0 mentions for Gemini Therapeutics. Qiagen's average media sentiment score of 0.88 beat Gemini Therapeutics' score of 0.00 indicating that Qiagen is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Neutral Qiagen Positive Do analysts prefer GMTX or QGEN? Qiagen has a consensus price target of $49.69, suggesting a potential upside of 9.47%. Given Qiagen's stronger consensus rating and higher probable upside, analysts clearly believe Qiagen is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27 Which has more volatility and risk, GMTX or QGEN? Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. SummaryQiagen beats Gemini Therapeutics on 13 of the 15 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.59B$840.61M$5.80B$10.17BDividend YieldN/A4.84%5.72%4.61%P/E Ratio-59.821.1475.0526.39Price / SalesN/A26.51544.00190.24Price / CashN/A19.5625.8129.91Price / Book20.706.6613.436.28Net Income-$71.87M-$4.13M$3.29B$270.38M7 Day Performance-3.38%1.76%0.08%1.89%1 Month Performance-0.07%8.04%4.61%6.01%1 Year Performance25.17%27.75%75.02%25.26% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$59.82-0.8%N/A+25.2%$2.59BN/A-59.8230QGENQIAGEN4.4448 of 5 stars$47.23-0.7%$49.69+5.2%+0.7%$10.50B$1.98B27.905,765Positive NewsBBIOBridgeBio Pharma4.4092 of 5 stars$53.21-2.0%$63.35+19.1%+96.6%$10.18B$221.90M-13.02400Analyst ForecastMRNAModerna4.5366 of 5 stars$24.44-1.6%$42.88+75.5%-65.0%$9.50B$3.24B-3.245,800ELANElanco Animal Health2.6271 of 5 stars$18.63-2.2%$17.33-6.9%+28.7%$9.24B$4.44B21.639,000VRNAVerona Pharma PLC American Depositary Share2.3188 of 5 stars$106.280.0%$109.00+2.6%+257.2%$9.19B$42.28M-107.3530Positive NewsROIVRoivant Sciences3.1466 of 5 stars$13.25+2.6%$16.38+23.6%+16.8%$9.04B$29.05M-18.91860Positive NewsRVMDRevolution Medicines4.1932 of 5 stars$40.93-0.3%$72.00+75.9%+5.7%$7.64B$11.58M-9.09250Insider TradeAnalyst RevisionGRFSGrifols3.9957 of 5 stars$9.96-1.5%$10.30+3.4%+4.0%$6.84B$7.45B8.5123,822Positive NewsGap UpABVXAbivax2.3952 of 5 stars$89.34-0.7%$95.14+6.5%+632.7%$6.75BN/A0.0061Analyst UpgradeShort Interest ↑Gap DownRYTMRhythm Pharmaceuticals3.275 of 5 stars$99.730.0%$101.57+1.8%+93.5%$6.62B$130.13M-33.12140Positive News Related Companies and Tools Related Companies QIAGEN Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Elanco Animal Health Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Grifols Alternatives Abivax Alternatives Rhythm Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GMTX Stock Alerts